uniQure to Participate in Multiple Upcoming Industry Conferences in March

LEXINGTON, Mass. and AMSTERDAM, March 03, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in March:

• Cowen 40^th Annual Health Care Conference, March 2 – 4, Boston, MA.
  
  
  
  • , chief executive officer at uniQure, will be presenting a corporate update today, March 3, at 9:20 a.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event. Members of uniQure’s management team also will participate in one-on-one investor meetings throughout the day.
  
   
• Gene Therapy for Blood Disorders Conference, March 3 – 5, Boston, MA.
  
  
  
  • , M.D., Ph.D., executive vice president, research & product development at uniQure, will present “Evaluating Immunogenic Responses in Systemic Administration: Determining the ‘Right’ Dose” on Wednesday, March 4, at 3:45 p.m. ET.
  
  
  
  • Eileen Sawyer, Ph.D., vice president, global medical affairs of uniQure, will participate in a panel discussion: “Assessing the Commercial Realities of Launching Gene Therapies in the Blood Disorder Space”, on Wednesday, March 4, at 9:15 a.m. ET.
  
   
• BioCapital Europe by LSP, March 12, Amsterdam, the Netherlands.
  
  
  
  • A corporate update will be presented by , chief accounting officer of uniQure, on Thursday, March 12, at 9:30 a.m. CET.
  
   
• 2020 Summit Meeting on in vivo Gene Therapy and Editing Presented by Chardan, March 23 – 24, Miami, FL.
  
  
  
  • Sander van Deventer will present on the Company’s clinical development for hemophilia B on Monday, March 23, at 2:20 p.m. ET, and participate in a panel discussion on AAV gene therapy March 23 at 3:45 p.m. ET.
  
   
• 4^th Annual Gene Therapy for Rare Disorders 2020 Summit, March 30 – April 2, Boston, MA.
  
  
  
  • , Ph.D., executive vice president operations at uniQure, will present “Extracting Meaningful Data from Clinical Trials to Present to Regulatory Agencies” on Tuesday, March 31, at 2:30 p.m. ET.
  
   
• Clinical Biomarkers & World CDx Europe 2020 Conference, March 31 – April 1, London, U.K.
  
  
  
  • Astrid Valles-Sanchez, Ph.D., senior scientist at uniQure will be presenting “Translatable Biomarkers in Gene Therapy for Huntington Disease: Innovative Approaches & Learnings from Pre-Clinic to the Clinic” on Tuesday, March 31, at 3:30 p.m. GMT. 
  
  
  
  • In addition, she will participate in the panel discussion “Precision Medicine Beyond Oncology” on March 31, at 4:30 p.m. GMT. 

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts: